Teva (TEVA +5.6%) and Active Biotech (ATVBF.PK) announce their Phase III study of laquinimod, a...

|About: Teva Pharmaceutical Indu... (TEVA)|By:, SA News Editor

Teva (TEVA +5.6%) and Active Biotech (ATVBF.PK) announce their Phase III study of laquinimod, a drug for multiple-sclerosis, met its primary endpoint and led to a "statistically significant reduction" in relapse rates compared to a placebo.